Background. The clinical effectiveness of the double-carbapenem combination therapy in mechanically ventilated patients with carbapenemase-producing carbapenem-resistant Enterobacteriaceae bloodstream septic shock infection is not well studied.
Background. Evaluations of clinical use and real-world outcomes following C/T treatment exist; however, data assessing outcomes in IC patients are limited. This study evaluated treatment patterns and clinical outcomes of IC patients treated with C/T for MDR PA across 15 US hospitals.
Methods. Adult IC inpatients treated for ≥ 24 hours with C/T admitted between 12/14-5/18 for MDR PA infections were included in this retrospective multicenter cohort study. IC was defined as patients with previous solid-organ transplant (SOT), diseases that suppress resistance to infection (HIV/AIDS, leukemia, lymphoma), or receipt of immunosuppressants, chemotherapy, radiation, long-term low-dose (≥ 1 month) or recent high-dose steroids (> 5 days). Clinical and microbiologic data were extracted from electronic records. The primary outcomes were all-cause 30-day mortality and clinical cure, defined as no escalation/additional therapy and improved signs and symptoms from baseline to end of therapy. PA isolates were characterized as MDR if non-susceptible to ≥ 3 classes of antipseudomonal agents. Classification and regression tree (CART) analysis was used to identify the 30-day mortality split in APACHE II scores.
Results. Seventy patients were included; 58 (83%) had received immunosuppressive agents, 47 (67%) had history of SOT, and 19 (27%) had diseases suppressing resistance to infection. Mean patient age was 57 ± 14 years, median (interquartile range) patient APACHE II and Charlson Comorbidity Index scores were 18 (12.5) and 5 (3.75), respectively, with 33 (47%) receiving ICU care at C/T initiation. The most frequent infection sources were respiratory (56%), wound (11%), intraabdominal (10%), and blood and urine (9% each), with 36% having a polymicrobial culture. All-cause 30-day mortality was 19% (n = 13) with clinical cure achieved in 48 (69%) patients. CART analysis identified the 30-day mortality split at APACHE II score > 25 (76% vs. 24%; P = 0.002).
Conclusion. Of 70 IC patients treated with C/T for MDR PA, clinical cure was achieved in 69% and mortality was 19%, consistent with other evaluations reporting on a cross section of patient populations. C/T represents a promising agent for treatment of PA resistant to many traditional antipseudomonal agents in this high-risk population. Background. Currently, carbapenems are the treatment of choice for invasive infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E). However, clinical data supporting this practice are generated largely from cases caused by ESBL-producing Escherichia coli. We aimed to describe the empiric treatments and clinical outcomes of patients infected with ESBL-producing Klebsiella pneumoniae (ESBL-Kp) at UPMC Presbyterian Hospital in Pittsburgh, PA.
Methods. This retrospective study included all adult patients from inpatient admissions at UPMC Presbyterian Hospital who were diagnosed with ESBL-Kp infections. Carbapenem-resistant cases were excluded. Types of cultures included blood, respiratory, urine, and wound. Only one type of culture per patient was included. Demographic and clinical data were collected from the electronic medical records. The study was approved by the University of Pittsburgh IRB.
Results.
One-hundred sixty-four patients had ESBL-Kp infection between September 2016 and August 2018. Excluded were those who were considered colonized by the organism and therefore not treated (n = 15); treated with non-carbapenems as definitive therapy (n = 29); or were discharged before final susceptibilities (n = 14). In total, 70 patients met inclusion criteria. Eighteen had bacteremia, 24 had pneumonia, 13 had UTI, and 12 had wound infections. Most common sources of bacteremia included catheter-associated, intra-abdominal infection, and pneumonia. Median age of patients was 62 years. Mean Charleston Comorbidity Index was 4.6. Empiric treatment was divided between three classes: BL-BLI (n = 27, 38.6%), cephalosporins (n = 21, 30%) and carbapenems (n = 18, 25.7%). Twelve patients (17.1%) died during hospitalization. Average hospital length-of-stay was 33.2 days.
Conclusion.
Although infections with ESBL-Kp are relatively uncommon, patients have high mortality and prolonged hospitalizations. Treatment practices, including which infections are considered colonization vs. true infection, as well as choice of empirical therapy, vary widely at our institution. Data are still needed to assess mortality outcomes in patients treated empirically with carbapenems vs. non-carbapenems, particularly in high-inoculum infection sites such as pneumonia.
